ATAI News and Press, ATAI Life Sciences N.V. From 06/01/23

SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces the appointment of Greg...

NEW YORK and BERLIN, June 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in upcoming June Investor Conferences. Details of th...

A recent study has indicated that a nonhallucinogenic form of LSD may be able to treat mood disorders. LSD is one of several psychedelics that have recently gained attention from the scientific community as potential treatments for mental health conditions. Initial psychedelic studies have pr...

2023-05-25 06:07:22 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to investing, penny stocks often evoke a sense of intrigue and opportunity. These low-priced securities, typically traded under $5 per share, can potentially deliver substanti...

Last year, the Stanley Brothers signed a partnership between a professional sports league and a hemp/marijuana brand, becoming the first to do so. Prior to this, the company’s CBD products, including Charlotte’s Web, had been gaining popularity in Colorado, especially after a sur...

Studies have, in the past, associated the dilation of pupils, unexpected saccades and trippy details with the consumption of drugs such as DMT, psilocybin mushrooms and LSD. Now, a new case study has established a link between human vision and psychedelic substances. This may be the first study...

2023-05-11 09:23:10 ET ATAI Life Sciences press release ( NASDAQ: ATAI ): Q1 GAAP EPS of -$0.21 in-line. Revenue of $0.04M. Cash and cash equivalents and short-term investments totaled $249.9 million as of March 31, 2023, compared to $273.1 million of December 31, 2022...

RL-007: First patient dosed in the Phase 2b study of RL-007 in Cognitive Impairment Associated with Schizophrenia. GRX-917: Presented PD data from the completed Phase 1 study, which suggest the potential for anxiolytic effects without the significant sedative effects seen with benzodiazep...

A recent study has found combining psychedelics and sex may offer individuals an enhanced mental and physical pleasure experience. A new series, titled “PSYC Taboo,” will explore the potential for mind-blowing orgasms and solo psychedelic experiences, as more people try alternativ...

NEW YORK and BERLIN, May 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Aegis Virtual Conference. Details of the ...